- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Indomethacin effective for closing symptomatic PDA in preterm infants: Cochrane Review
Canada: Indomethacin may be effective in closing a symptomatic PDA in preterm infants as compared to placebo or no treatment, according to a recent Cochrane review. However, according to the authors, evidence is insufficient regarding indomethacin effects on medication-related adverse effects and clinically relevant outcomes.
Symptomatic patent ductus arteriosus (PDA) increases risk of morbidity and mortality in preterm infants. The use of indomethacin, a non-selective cyclooxygenase inhibitor, has shown short-term clinical benefits in these infants. However, the effect of indomethacin in preterm infants with a symptomatic PDA is still not explored. Souvik Mitra, Dalhousie University & IWK Health Centre, Halifax, Canada, and colleagues aimed to determine the safety and efficacy of indomethacin versus placebo or no treatment in reducing mortality and morbidity in preterm infants with a symptomatic PDA.
For the purpose, the researchers used the standard search strategy of Cochrane Neonatal to search for Cochrane Central Register of Controlled Trials on 31 July 2020. Clinical trials databases and reference lists of retrieved articles were searched for randomized controlled trials (RCTs) and quasi‐RCTs.
It included RCTs and quasi‐RCTs that compared indomethacin (any dose, any route) versus placebo or no treatment in preterm infants. A total of 14 RCTs consisting of 880 preterm infants were included.
Key findings of the study include:
- Four out of the 14 included studies were judged to have high risk of bias in one or more domains.
- Indomethacin administration was associated with a large reduction in failure of PDA closure within one week of administration of the first dose (risk ratio (RR) 0.30; 10 studies, 654 infants; high‐certainty evidence).
- There may be little to no difference in the incidence of BPD (BPD defined as supplemental oxygen need at 28 days' postnatal age: RR 1.45; 1 study, 55 infants; low‐certainty evidence; BPD defined as supplemental oxygen need at 36 weeks' postmenstrual age: RR 0.80; 1 study, 92 infants; low‐certainty evidence) and probably little to no difference in mortality (RR 0.78; 8 studies, 314 infants; moderate‐certainty evidence) with use of indomethacin for symptomatic PDA. No differences were demonstrated in the need for surgical PDA ligation (RR 0.66; 7 studies, 275 infants; moderate‐certainty evidence), in NEC (RR 1.27; 2 studies, 147 infants; low‐certainty evidence), or in mucocutaneous or gastrointestinal bleeding (RR 0.33; 2 studies, 119 infants; low‐certainty evidence) with use of indomethacin compared to placebo or no treatment.
- Certainty of evidence for BPD, surgical PDA ligation, NEC, and mucocutaneous or gastrointestinal bleeding was downgraded for very serious or serious imprecision.
"High‐certainty evidence shows that indomethacin is effective in closing a symptomatic PDA compared to placebo or no treatment in preterm infants. Evidence is insufficient regarding effects of indomethacin on other clinically relevant outcomes and medication‐related adverse effects," wrote the authors.
The review titled, "Indomethacin for symptomatic patent ductus arteriosus in preterm infants," is published in Cochrane Library.
DOI: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/full
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751